Courses Description and Target Audience - The Annual Summer in Advanced Rheumatology is an interactive course for rheumatologists, internists, and those in the rheumatic diseases. It addresses a diverse array of topics from basic mechanisms of disease to advanced clinical issues. The course includes the latest data, including updates on clinical trials and new pharmacologic agents. It is designed to keep up with the ever-changing landscape of rheumatologic research and treatment, and to provide practical tools for researchers, clinicians, and other health professionals. The target audience includes rheumatologists, internists, and other healthcare professionals who are involved in the care of patients with rheumatic diseases.

Statement of Need - Lupus management remains a core performance area in which rheumatologists require an updated understanding of the latest diagnostic and treatment approaches, including new therapies and their potential impact on patient outcomes. The course will feature presentations by experts in the field, who will discuss the latest research and treatment options for lupus and other inflammatory conditions.

Rheumatology is a fast-moving field in which new discoveries are continually being made, and new treatment approaches are emerging. This course will provide an overview of the latest developments in the field, as well as an opportunity for attendees to discuss their own experiences and challenges. The course will cover a range of topics, including the latest research on the pathophysiology, treatment, and prevention of lupus, as well as the role of genetics and cytokines in its development. There will be a strong focus on new treatment approaches, including the potential for new agents in the near future, as well as new thinking in regards to pathophysiology, and the role of genetics and cytokines.

Educational Objectives -
- Examine the key concepts and latest findings in the field of lupus management, including the latest research on the pathophysiology, treatment, and prevention of lupus, as well as the role of genetics and cytokines in its development.
- Explore the latest treatment approaches, including new therapies and their potential impact on patient outcomes.
- Discuss the latest research on the pathophysiology, treatment, and prevention of lupus, as well as the role of genetics and cytokines in its development.
- Examine the key concepts and latest findings in the field of lupus management, including the latest research on the pathophysiology, treatment, and prevention of lupus, as well as the role of genetics and cytokines in its development.
- Explore the latest treatment approaches, including new therapies and their potential impact on patient outcomes.
- Discuss the latest research on the pathophysiology, treatment, and prevention of lupus, as well as the role of genetics and cytokines in its development.
Thursday, March 24, 2011

8:00 am Registration & Breakfast

9:00 am Welcome and Overview

9:15 am Recent Advances in Early Rheumatoid Arthritis

9:40 am Early Treatment in Rheumatoid Arthritis

10:15 am Coffee Break

11:00 am Recent Advances in Psoriatic Arthritis

11:35 am Psoriatic Arthritis: Research Registry

12:00 pm Lunch

1:00 pm Recent Advances in Connective Tissue Diseases

1:35 pm Recent Advances in Scleroderma

2:10 pm Coffee Break

2:30 pm Recent Advances in Systemic Lupus Erythematosus

3:05 pm Challenges in Lupus
discussion of unlabeled or unapproved uses of any drug, device or procedure

3:40 pm Lunch

4:15 pm Recent Advances in Ankylosing Spondylitis

4:50 pm Recent Advances in Osteoarthritis

5:25 pm Coffee Break

6:00 pm Social Reception

Friday, March 25, 2011

8:00 am Registration & Breakfast

9:00 am Recent Advances in Juvenile Arthritis

9:40 am Juvenile Arthritis: Outcomes and Monitoring in Routine Care

10:15 am Coffee Break

10:30 am Recent Advances in Connective Tissue Diseases

11:05 am Discovery of New Therapies in SLE

11:40 am Recent Advances in Connective Tissue Diseases

12:15 pm Lunch

1:00 pm Recent Advances in Scleroderma

1:45 pm Recent Advances in Osteoarthritis

2:20 pm Coffee Break

2:45 pm Recent Advances in Ankylosing Spondylitis

3:20 pm Recent Advances in Osteoarthritis

4:05 pm Coffee Break

4:30 pm Recent Advances in Juvenile Arthritis

5:05 pm Recent Advances in Connective Tissue Diseases

5:40 pm Social Reception
Educational Objectives

- Facilitate new and future treatment approaches for lupus management as well as the role of specific immune cells, genetics, and cytokines in the pediatric use of lupus drugs and the potential to exploit these mechanisms for therapeutic targets.
- Update therapeutic approach for rheumatoid and psoriatic arthritis based on recognition of the benefits and management tools of available biologic therapies.
- Consider the cardiovascular risk associated with rheumatic disease when selecting treatment strategies for patients.
- Develop and implement management and treatment strategies based on the mechanisms of fibrosis in scleroderma and psoriasis and alluded on best approaches in treatment.
- Consider the mechanisms of current and pipeline urate-lowering and anti-inflammatory therapies and their significant role in good management.
- Update evaluation of music/dance therapy based on understanding of new indications for imaging using ultrasound and MRI.

Rheumatology is a fast-moving field in which new discoveries are continually being made, and new treatment modalities developed. Because of the lack of clinical evidence, the application of new rheumatologic products is frequently and directly come to impact upon therapy, this course will also explore those areas of new knowledge that are likely to prove important to the near-future management of patients with rheumatic disease.

Statement of Need - Lupus management remains a core performance area in which rheumatologists require updating as a number of novel research studies have shown that the positive therapeutic results for lupus diseases must be addressed. Clinicians need to be aware of new approaches to the treatment of lupus, including the understanding of pathophysics, and the role of genetics and cytokines.

There are also new approaches to the treatment of monoclonal and polyclonal, including newly-available biologic therapies, which clinicians should consider both from a safety and efficacy standpoint. Practicing Rheumatologists need to be aware that many rheumatologic diseases cause an increased risk for cardiovascular disease that must be addressed and/or managed. There is also a need to cover the predictability of increased morbidity and mortality of lupus patients who fail to receive chest x-rays.

Lastly, although current available treatments for gout are effective, new therapeutic agents have been needed for some time. Clinicians need to be made aware of these changes in the management of crystal diseases, including urate-lowering therapies in an era currently in the pipeline.

Advanced RHEUMATOLOGY

New York, NY

MARCH 24-26, 2011

CME Information

Course Description and Target Audience - The annual Seminar in Advanced Rheumatology is an informative setting for rheumatologists, residents, fellows in rheumatology and trainees with a special interest in rheumatology. The teaching faculty is a distinguished group of rheumatology specialists from across North America. It is a unique opportunity to get a glimpse of the ‘gray literature’, presenting the latest research and clinical advances in the field.

A full-day special workshop is provided the following day, offering an opportunity to explore additional aspects of the clinical and research field.

For more information or to register, please visit us online at nyupgms.edu for more information.

CME Course Director:

Sharon A. Rosenthal, MD
   Professor of Medicine
   NYU School of Medicine
   550 First Avenue, New York, NY 10016

Faculty:

Anca Dinu Askanase, MD, MPH
   Professor of Medicine and Clinical Professor of Dermatology
   Weill Cornell Medical College
   New York, NY

Bruce N. Cronstein, MD, PhD
   Clinical Professor of Medicine
   New York University School of Medicine
   New York, NY

Maxime Dougados, MD
   Director, Arthritis and Immune Disorders Research Centre
   La Jolla, CA

Michael J. Colin, MD
   Professor of Medicine
   Weill Cornell Medical College
   New York, NY

Michael H. Pillinger, MD, PhD
   Senior Investigator,
   Associate Director, Center for Innovative Health Research
   New York, NY

Nancy L. Lane, MD
   Professor of Medicine
   University of California, San Diego
   School of Medicine
   La Jolla, CA

Jonathan Kay, MD
   Professor of Medicine
   Harvard Medical School
   Boston, MA

Peter M. Izmirly, MD
   Assistant Professor of Medicine
   Cleveland Clinic
   Cleveland, OH

Soumya M. Reddy, MD
   Assistant Professor of Medicine
   The New York Hospital Cornell Medical Center
   New York, NY

Mark A. Eberle, MD
   Clinical Professor of Medicine
   Weill Cornell Medical College
   New York, NY

Jill P. Buyon, MD
   Professor of Medicine
   New York, NY

Mary K. Crow, MD
   Professor of Medicine
   New York, NY

Edward C. Keystone, MD, FRCPC
   Director of Medicine
   UC San Diego Health Science School of Medicine
   Toronto, ON Canada

Gerald B. Appel, MD
   Guest Faculty
   Toronto, ON Canada

Bruce N. Cronstein, MD
   Andre Pineo, MD
   Chief, Rheumatology Section
   New York, NY

Michael H. Pillinger, MD, PhD
   Senior Investigator
   Director of Medicine
   New York, NY

Arthur S. Kavanaugh, MD
   Professor of Medicine
   University of California, San Diego
   School of Medicine
   La Jolla, CA

Michael R. Masi, MD
   Director, Clinical Trial Health
   Duke University Medical Center
   Durham, NC

Leon D. Rybak, MD
   Assistant Professor
   Temple University School of Medicine
   Philadelphia, PA

Michael J. Colin, MD
   Assistant Professor of Medicine
   New York, NY

Jill P. Buyon, MD
   Professor of Medicine
   New York, NY

Jonathan Kay, MD
   Professor of Medicine
   Harvard Medical School
   Boston, MA

George T. Tsokos, MD
   Professor of Medicine
   Harvard Medical School
   Boston, MA

David S. Pisetsky, MD
   Research Professor and Head of Arthritis and Immunology
   Duke University Medical Center
   Durham, NC

Bruce N. Cronstein, MD
   Foundation Professor of Medicine
   New York University School of Medicine
   New York, NY

Gerald Weissmann, MD, MACR
   Adjunct Faculty
   New York, NY

NYU School of Medicine & NYU Hospital for Joint Diseases Faculty

Course Director:

Sharon A. Rosenthal, MD
   Professor of Medicine
   NYU School of Medicine
   550 First Avenue, New York, NY 10016

Faculty:

H. Michael Belmont, MD
   Clinical Assistant Professor of Medicine
   Columbia University College of Physicians and Surgeons
   New York, NY

Iain D. Macintyre, MD
   Associate Professor of Medicine
   Weill Cornell Medical College
   New York, NY

Anca Dinu Askanase, MD, MPH
   Professor of Medicine
   Weill Cornell Medical College
   New York, NY

Mark A. Eberle, MD
   Clinical Professor of Medicine
   Weill Cornell Medical College
   New York, NY

Jill P. Buyon, MD
   Professor of Medicine
   New York, NY

Mary K. Crow, MD
   Professor of Medicine
   New York, NY

Edward C. Keystone, MD, FRCPC
   Director of Medicine
   UC San Diego Health Science School of Medicine
   Toronto, ON Canada

Gerald B. Appel, MD
   Guest Faculty
   Toronto, ON Canada

Bruce N. Cronstein, MD
   Andre Pineo, MD
   Chief, Rheumatology Section
   New York, NY

Michael H. Pillinger, MD, PhD
   Senior Investigator
   Director of Medicine
   New York, NY

Arthur S. Kavanaugh, MD
   Professor of Medicine
   University of California, San Diego
   School of Medicine
   La Jolla, CA

Michael R. Masi, MD
   Director, Clinical Trial Health
   Duke University Medical Center
   Durham, NC

Leon D. Rybak, MD
   Assistant Professor
   Temple University School of Medicine
   Philadelphia, PA

Michael J. Colin, MD
   Assistant Professor of Medicine
   New York, NY

Jill P. Buyon, MD
   Professor of Medicine
   New York, NY

Jonathan Kay, MD
   Professor of Medicine
   Harvard Medical School
   Boston, MA

George T. Tsokos, MD
   Professor of Medicine
   Harvard Medical School
   Boston, MA

David S. Pisetsky, MD
   Research Professor and Head of Arthritis and Immunology
   Duke University Medical Center
   Durham, NC

Bruce N. Cronstein, MD
   Foundation Professor of Medicine
   New York University School of Medicine
   New York, NY

Gerald Weissmann, MD, MACR
   Adjunct Faculty
   New York, NY

Special Workshops

- State of the Art Lectures
- Meet the Professor Lunches
- Usefulness of X-rays and MRI
- Bone Fractures: Clinical and laboratory diagnosis
- Clinical and laboratory diagnosis of the Office Setting
- Ultrasound in the Office Setting
Lastly, although current available treatments for gout are effective, new therapeutic agents have been needed for approaches in the intermediate future and how that translates to treatment of scleroderma and myositis. Accumulating understanding about the mechanisms of fibrosis in scleroderma that is likely to lead to new interventions is necessary. Consider the cardiovascular risk associated with rheumatic disease when selecting treatment strategies for patients. This course will also explore those areas of new knowledge that are likely to prove important to the near-future management of patients with rheumatic disease.

Statement of Need - Lupus management remains a core performance area in which rheumatology requires excellence as a number of recent research results have shown for indications that are not yet generally transferred to practice. Clinicians need to be aware of newer approaches to the treatment of lupus, including the expanding use of biologic therapies, and their specific roles in gout management. Upadate evaluation of musculoskeletal disease based on understanding of new indications for imaging using ultrasonohraphy and/or MRI. Develop and implement management and treatment strategies based on the mechanisms of fibrosis in scleroderma and directly come to impact upon therapy, this course will also explore those areas of new knowledge that are likely to prove important to the near-future management of patients with rheumatic disease.
Thursday, March 24, 2011

3:30 - 6:30 Workshops on Clinical Dilemmas and Research in the Office Setting
   1) Novel Approaches to the Therapy of RA – Carter F. Ramsay, MD – 8:00
   2) Lupus Nephritis: New Insights into the Pathogenesis of IL-6 and IL-10 – Bruce N. Cronstein, MD, PhD – 9:00
   3) Treating Vasculitis – Pranath H. Bhattacharyya, MD – 10:00
   4) Chronic Arthritis: Practical Treatment of Inflammatory Joint Disease – Jonathan Kay, MD – 11:00

5:30 - 7:30 Optional AM Workshops on Clinical Databases and Research in the Office Setting
   1)EDesign: Use of a Web-Based Questionnaire to Assess Adherence to Treatment Protocols – Randy C. Blackman, MD – Microvascular Microparticles as Mediators of Inflammatory Responses – Eric F. Wagner, MD – 8:30
   2) E-mail – Preventing Underuse of Rheumatoid Drugs in the Office Setting – Joan H. Walker, MD – 9:30
   3)Pharmacoeconomics – Clinical Evaluation of New Drugs – Stuart F. Wecht, MD – 10:30
   4)Cost Effectiveness of Biologic Therapy – James W. Coates, MD – 11:30

7:30 - 9:30 Optional AM Workshops on Clinical Databases and Research in the Office Setting
   1)New Biomedical Research Opportunities: Database Construction – Michael H. Pillinger, MD – 8:00
   2)What’s New in Clinical Trials? – Michael A. Kalluri, MD, PhD – 9:00
   3)A New Tool for Teaching Pharmacology in Rheumatology – Daniel C. Langman, MD, PhD – 10:00
   4)Clinical Trials: From Research Design to Outcome Analysis – Emran H. Fazel, MD – 11:00

Monday, March 21, 2011

1:00 - 1:15 Opening Remarks
   1:15 - 2:30 Keynote Address: The Clinical Year in Review: Osteoarthritis and Osteoporosis – Jonathan Samuels, MD – 1:15
   2:30 - 3:30 Chair: Richard F. Salaff, MD – "Should It Be a Patient’s Right to Refuse Treatment?" – Henry R. Lambert, MD – 2:30
   3:30 - 4:30 Concurrent Paper Session: Osteoarthritis and Osteoporosis

Tuesday, March 22, 2011

7:30 - 9:30 Morning Keynote: Lupus Trials
   1)Chair: Jill P. Buyon, MD – 7:30
   2)Novel Approaches for Lupus Nephritis – Richard F. Salaff, MD – 8:00
   3)Cutaneous Manifestations of SLE and Related Dermatoses: Microparticles as Mediators of Inflammatory Responses – Eric F. Wagner, MD – 9:00
   4)Panel Discussion: Lupus Nephritis – Chair: Michael O. Dicker, MD – 10:00

Wednesday, March 23, 2011

1:00 - 1:15 Opening Remarks
   1:15 - 2:15 Keynote Address: Arthritis Outcomes and Monitoring in Routine Care – Jonathan Samuels, MD – 1:15
   2:15 - 3:30 Concurrent Paper Session: Arthritis Outcomes and Monitoring in Routine Care

Thursday, March 24, 2011

3:30 - 6:30 Workshops on Clinical Dilemmas and Research in the Office Setting
   1)Treating Vasculitis – Pranath H. Bhattacharyya, MD – 8:00
   2)Chronic Arthritis: Practical Treatment of Inflammatory Joint Disease – Jonathan Kay, MD – 9:00
   3)EDesign: Use of a Web-Based Questionnaire to Assess Adherence to Treatment Protocols – Randy C. Blackman, MD – 10:00
   4)Pharmacoeconomics – Clinical Evaluation of New Drugs – Stuart F. Wecht, MD – 11:00

5:30 - 7:30 Optional AM Workshops on Clinical Databases and Research in the Office Setting
   1)New Biomedical Research Opportunities: Database Construction – Michael H. Pillinger, MD – 8:00
   2)What’s New in Clinical Trials? – Michael A. Kalluri, MD, PhD – 9:00
   3)A New Tool for Teaching Pharmacology in Rheumatology – Daniel C. Langman, MD, PhD – 10:00
   4)Clinical Trials: From Research Design to Outcome Analysis – Emran H. Fazel, MD – 11:00

7:30 - 9:30 Optional AM Workshops on Clinical Databases and Research in the Office Setting
   1)New Biomedical Research Opportunities: Database Construction – Michael H. Pillinger, MD – 8:00
   2)What’s New in Clinical Trials? – Michael A. Kalluri, MD, PhD – 9:00
   3)A New Tool for Teaching Pharmacology in Rheumatology – Daniel C. Langman, MD, PhD – 10:00
   4)Clinical Trials: From Research Design to Outcome Analysis – Emran H. Fazel, MD – 11:00

Registration and Continental Breakfast

8:00 - 9:00 Registration and Continental Breakfast

9:00 - 10:00 Chair: Michael O. Dicker, MD – 9:00
   1)Can We Prevent Underuse of Rheumatoid Drugs in the Office Setting? – Stuart F. Wecht, MD – 9:00
   2)Clinical Trials: From Research Design to Outcome Analysis – Emran H. Fazel, MD – 10:00

10:00 - 11:00 Concurrent Paper Session: Arthritis Outcomes and Monitoring in Routine Care
SAVE THE DATE
Wednesday, March 22, 2011
Program:
Registration
Registration Office: New York, NY 10016
FAX: 212-263-5295
Phone: 212-263-5293
www.cme.med.nyu.edu/rheumatology
Speakers:

Online Registration Protocol
Seating will be available on a first-come, first-served basis.

Registration Information
The NYU Post-Graduate Medical School is accredited by the</the end of the third paragraph>

Spring 2011

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:

Speakers:
**Pain Etiology of Childhood Musculoskeletal Syndromes, Juvenile Dermatomyositis, CME Afternoon Program**

**Wednesday, March 23, 2011**

**Save the Date**

**PHOTO IDENTIFICATION IS REQUIRED**

**Location**

- 8:00 pm Performance of MEMPHIS their participation in the activity.
- Maximum of 17 AMA PRA credits
- AMA PRA Category 1 Credit Designation Statement

The NYU Post-Graduate Medical School

**Disclosure Statement**

- Inflammatory Arthritis

- Clinical Developments in Inflammatory Arthritis

- Myositis and Fibromyalgia

- Seronegative Arthritides and Their Therapy

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising for SLE: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising

- Pathogenesis and Treatment of Osteoarthritis

- Clinical Year in Review: Emerging Biomarkers

- Clinical Year in Review: New Treatments in SLE

- Lupus Nephritis: Mycophenolate Mofetil and Beyond

- Lupus Nephritis: The Approved and the Promising
Educational Objectives
- Explain new and future treatment approaches for lupus management as well as the role of specific immune cells, genetics and cytokines in the pathogenesis of lupus and the potential to exploit these mechanisms for therapeutic targets.
- Update therapeutic approach for rheumatoid and psoriatic arthritis based on recognition of the benefits and manage risks of newly available biologic therapies.
- Consider the cardiovascular risk associated with rheumatic disease when selecting treatment strategies for patients.
- Develop and implement management and treatment strategies based on the mechanisms of fibrinolysis in scleroderma and myositis and the potential to exploit these mechanisms for therapeutic targets.
- Consider the mechanisms of current and future biologic therapies and their significant role in good patient care.
- Update evaluation of musculoskeletal disease based on understanding of new indicators for imaging using ultrasonography and MRI.